Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists (2024)

Article Navigation

Volume 17 Issue 8 August 2015

Article Contents

  • Abstract

  • Introduction

  • Methods

  • Results

  • Discussion

  • Conclusion

  • Funding

  • References

  • < Previous
  • Next >

Journal Article

,

Pasquale Pignatelli

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

These authors contributed equally.

Search for other works by this author on:

Oxford Academic

,

Daniele Pastori

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

These authors contributed equally.

Search for other works by this author on:

Oxford Academic

,

Tommasa Vicario

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Tommaso Bucci

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Maria Del Ben

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Roberta Russo

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Alessandra Tanzilli

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Maria Lavinia Nardoni

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Simona Bartimoccia

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Cristina Nocella

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

... Show more

,

Domenico Ferro

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Mirella Saliola

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Roberto Cangemi

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

Search for other works by this author on:

Oxford Academic

,

Gregory Y.H. Lip

2

University of Birmingham Centre for Cardiovascular Sciences, City Hospital

,

Birmingham

,

UK

These are joint senior authors.

Search for other works by this author on:

Oxford Academic

Francesco Violi *

1

Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties

,

Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica

,

Viale del Policlinico 155

,

Rome 00161

,

Italy

These are joint senior authors.

Search for other works by this author on:

Oxford Academic

These authors contributed equally.

These are joint senior authors.

Author Notes

EP Europace, Volume 17, Issue 8, August 2015, Pages 1223–1228, https://doi.org/10.1093/europace/euv127

Published:

20 May 2015

Article history

Received:

30 December 2014

Accepted:

07 April 2015

Published:

20 May 2015

  • PDF
  • Split View
  • Views
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
  • Cite

    Cite

    Pasquale Pignatelli, Daniele Pastori, Tommasa Vicario, Tommaso Bucci, Maria Del Ben, Roberta Russo, Alessandra Tanzilli, Maria Lavinia Nardoni, Simona Bartimoccia, Cristina Nocella, Domenico Ferro, Mirella Saliola, Roberto Cangemi, Gregory Y.H. Lip, Francesco Violi, Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists, EP Europace, Volume 17, Issue 8, August 2015, Pages 1223–1228, https://doi.org/10.1093/europace/euv127

    Close

Search

Close

Search

Advanced Search

Search Menu

Abstract

Aims

It is unclear if atrial fibrillation (AF) patients treated with oral vitamin K antagonists (VKAs) must follow a specific diet to avoid interference with anticoagulation. The aim of this study was to assess if Mediterranean diet (Med-Diet) may affect quality of anticoagulation, as expressed by the time in therapeutic range (TTR).

Methods and results

A prospective observational study including 553 non-valvular AF patients. Time in therapeutic range was calculated for all patients treated with VKAs, and adherence to Med-Diet was evaluated with a validated nine-item dietary questionnaire. Cardiovascular events (CVEs), such as cardiovascular death and fatal/non-fatal stroke or myocardial infarction, and bleedings were recorded. The median follow-up was 31.6 months. The median number of international normalized ratios for each patient was 63.0 (35.0–98.0) and 38 730 blood samples were analysed. In the whole cohort, the mean TTR was 65.5 ± 17.8%. The mean Med-Diet score was 5.19 ± 1.6, with frequent use of olive oil (90.1%), fruits (88.4%), and vegetables (69.3%) and low meat intake (71.2%). There were no differences among tertiles of Med-Diet score regarding TTR. A multivariable linear regression analysis showed that diabetes (β: −0.105, P = 0.015) and the use of angiotensin converting enzyme inhibitor/angiotensin receptor blockers (β: 0.153, P < 0.001) were associated with TTR. Compared with those without, AF patients with a CVE had significantly lower TTR (65.9 ± 17.9 vs. 59.6 ± 15.9, P = 0.029) and Med-Diet score (5.2 ± 1.5 vs. 4.4 ± 1.9, P = 0.004). A reduction of CVE was observed for each point of the Med-Diet score (hazard ratio 0.790, P = 0.017).

Conclusion

In our cohort of AF patients, Med-Diet is not associated with changes in TTR, and thus can be recommended for AF patients who are taking VKAs.

Atrial fibrillation, Mediterranean diet, Time in therapeutic range, Vitamin K, Food–drug interaction, Cardiovascular events

What's new?

  • The common belief is that the intake of some foods rich of vitamin K, such as leafy greens vegetables, may interfere with anticoagulation.

  • As Med-Diet is rich in fruits and vegetables, we analysed if adherence to Med-Diet had a negative impact on the TTR in 553 patients with AF on treatment with VKAs.

  • The study demonstrates that adherence to Med-Diet was not associated with changes in TTR, so suggesting that a food rich in fruits and vegetables actually does not interfere with anticoagulation by VKAs.

  • An important clinical implication of this finding is that Med-Diet could represent a dietary option for AF patients on treatment with VKAs.

Introduction

In patients with atrial fibrillation (AF) taking vitamin K antagonists (VKAs), recorded international normalized ratio (INR) values outside the therapeutic range of 2.0–3.0, as reflected by the average individual time in therapeutic range (TTR), are still common despite major efforts from healthcare providers to adjust drug dosages and educate patients. This represents an important clinical challenge, since TTR inversely correlates with thrombosis, mortality, and bleeding.1 Thus, VKAs are underused in clinical practice because of physicians' fear of erratic anticoagulation control and increased risk of bleeding, especially in the elderly.2

Educational advice and counselling is often given to AF patients starting VKAs, in order to improve adherence of patients to treatment and to enhance anticoagulation stability and better TTRs, and a great emphasis is still made on diet and nutritional information.3

There are few (and often inconclusive) studies4–6 investigating the influence of dietary habits on the anticoagulation quality, and guidelines still do not provide sufficient indication about the more appropriate dietary approaches to maintain a good TTR in VKA-anticoagulated AF patients.7 Particular attention has been classically focused on vitamin K-rich foods, such as dark-green leafy vegetables, which could interfere with VKA anticoagulation stability.8,9 The Mediterranean diet (Med-Diet) is characterized by a high intake of vitamin K-rich foods, such as green vegetables, and therefore, could represent a unique tool to establish if a diet rich in fruits and vegetables may interfere with TTR. Thus far, the interplay between Med-Diet adherence and TTR in AF patients has never previously been examined.

In the present study, we report for the first time the results of a prospective study evaluating the relationship between adherence to Med-Diet and TTR in a large AF population on chronic VKA treatment.

Methods

In this prospective, single-centre, observational cohort study, we consecutively recruited 600 AF patients receiving oral anticoagulants from I Medical Clinic, Atherothrombosis Center of Sapienza University of Rome, where patients are followed for the monitoring of INR and VKA dosage, from February 2008 to October 2013. All patients with non-valvular AF, aged >18 years were included in the study. All patients were treated with VKA (warfarin/acenocumarol) after appropriate risk stratification according to the CHA2DS2-VASc score (and previously according to CHADS2-Score).

Exclusion criteria: mechanical or biologic prosthetic valves, severe valvulopathies, congenital heart diseases, severe cognitive impairment (e.g. Alzheimer's disease, Parkinson's disease), and chronic inflammatory diseases. Furthermore, we excluded subjects with active neoplastic diseases, liver cirrhosis, or if they were taking any vitamin or antioxidant supplementation.

The presence of cardiovascular risk factors, such as arterial hypertension, diabetes and heart failure (HF), was assessed using international definitions, as previously described.10

Adherence to Mediterranean diet

Adherence to the Med-Diet was investigated by administration of a short dietary questionnaire that was elaborated by Martinez-Gonzalez et al.,11 and was assessed using a validated food-frequency questionnaire with 136 items. This short questionnaire included the following: (i) olive oil (≥1 spoon/day); (ii) fruit (≥1 serving/day); (iii) vegetables or salad (≥1 serving/day); (iv) both fruit (≥1 serving/day) and vegetables (≥1 serving/day); (v) legumes (≥2 servings/week); (vi) fish (≥3 servings/week); (vii) wine (≥1 glass/day); (viii) meat (<1 serving/day); (ix) [white bread (<1/day) and rice (<1/week)] or whole-grain bread (>5/week).11 At baseline, a doctor or nurse administered the questionnaire, and the patient was asked to respond thinking about his usual eating habits at home.

To track adherence to Med-Diet, we administered the questionnaire a second time during the follow-up (see below).

Follow-up

Follow-up visits were scheduled every 2–4 weeks for INR monitoring (therapeutic range of 2.0–3.0). Patients were asked to report to physician every change in dietary and medications. If a hospitalization occurred during the follow-up, the patient was required to submit medical documentation or copies of medical records.

Main outcome

Main outcome of the study was to analyse in AF patients, the quality of anticoagulation control, as assessed by TTR,12 in relation to the adherence to Med-Diet. Specifically, TTR was calculated with the method described by Rosendaal et al.,12 which uses linear interpolation of INR values to assign to each follow-up day a value of INR. Then, the percentage of days that the INR was in the therapeutic range was calculated for each patient.

Events during the follow-up

Definition and adjudication of cardiovascular and cerebrovascular events have been previously described.10 Bleeding events were classified according to the ISTH criteria, as previously reported13.

Statistical analysis

Categorical variables were reported as counts (percentage) and continuous variables as means ± standard deviation (SD) unless otherwise indicated. Independence of categorical variables was tested by χ2 test. Normal distribution of parameters was assessed by Kolmogorov–Smirnov test. Student's unpaired t-test and Pearson product-moment correlation analysis were used for normally distributed continuous variables. Appropriate non-parametric tests (Mann–Whitney U test and Spearman rank correlation test) were employed for all the other variables. For the analyses we divided the entire population according to tertiles of the total Med-Diet score obtained from the nine-item questionnaire:11 first tertile 0–4 points, second tertile 5 points, third tertile 6–9 points. Stepwise multivariable linear regression analysis was used to assess factors influencing TTR. Only P values <0.05 were considered as statistically significant. All tests were two-tailed and analyses were performed using computer software packages (SPSS-18.0, SPSS Inc.).

Written informed consent was obtained from all subjects. The study was approved by the local Ethics Committee of Sapienza University, and was conducted in accordance with the principles embodied in the Declaration of Helsinki.

Results

Of 600 screened patients, 18 were excluded from the analysis as follows: 6 because of active cancer, 8 for the presence of mechanical heart valve, 3 for severe cognitive impairment, and 1 for autoimmune disease. In addition, 5 patients refused to be included and 24 patients who were receiving supplements were excluded. Thus, 553 patients participated in the study. The median follow-up was 31.6 (15.1–47.6) months, yielding 1513 patient/years of observation. Clinical characteristics of AF population are reported in Table 1. Patients with AF had a clinical history complicated by myocardial infarction (MI)/cardiac revascularization in 20.3% and by ischaemic stroke/transient ischaemic attack (TIA) in 14.5%. Among the atherosclerotic risk factors, hypertension was detected in 87.5% and diabetes in 19.2%. The mean CHA2DS2-VASc score was 3.4 ± 1.5 in the entire population. In 10.8%, aspirin was combined with VKAs.

Table 1

Baseline characteristics of the study cohort

Overall (n = 553)First tertile of Med-Diet 0–4 points (n = 165)Second tertile of Med-Diet 5 points (n = 144)Third tertile of Med-Diet 6–9 points (n = 244)P*
Age (years)72.9 ± 8.372.5 ± 9.072.7 ± 9.373.3 ± 7.00.590
Gender (females) (%)40.042.444.435.70.173
Body mass index (kg/m2)27.3 ± 4.327.3 ± 4.827.8 ± 4.226.9 ± 4.00.121
CHA2DS2-VASc score3.4 ± 1.53.5 ± 1.63.3 ± 1.43.4 ± 1.50.405
Time in therapeutic range (%)65.5 ± 17.863.6 ± 16.567.4 ± 18.665.7 ± 18.20.172
Mean week dosage of warfarin (mg)26.0 ± 11.726.7 ± 10.626.0 ± 13.525.7 ± 11.00.812
Mean week dosage of acenocumarol (mg)14.7 ± 6.513.0 ± 5.416.6 ± 6.415.0 ± 7.00.022**
Number of INR analysis, n63.0 (35.0–98.0)74.0 (44.5–104.0)55.5 (32.2–92.5)64.0 (35.0–98.7)0.037***
Mean days between two controls (days)18.9 ± 7.119.1 ± 8.019.0 ± 6.318.6 ± 7.00.716
Past medical history
 Arterial hypertension (%)87.587.389.586.50.680
 Diabetes (%)19.220.618.218.90.850
 History of stroke/TIA (%)14.518.813.312.30.167
 Heart failure (%)14.317.69.115.20.092
 History of MI/CHD (%)20.321.216.821.70.476
 Number of drugs, n5.8 ± 2.45.7 ± 2.45.7 ± 2.55.9 ± 2.30.824
 Anti-platelet therapy (%)10.87.911.812.30.349
 ACE inhibitors/ARBs (%)73.670.774.375.30.582
 β-Blockers (%)42.142.739.743.00.812
 Ca-antagonists (%)33.836.630.933.60.580
 Amiodarone (%)30.730.133.129.80.784
Overall (n = 553)First tertile of Med-Diet 0–4 points (n = 165)Second tertile of Med-Diet 5 points (n = 144)Third tertile of Med-Diet 6–9 points (n = 244)P*
Age (years)72.9 ± 8.372.5 ± 9.072.7 ± 9.373.3 ± 7.00.590
Gender (females) (%)40.042.444.435.70.173
Body mass index (kg/m2)27.3 ± 4.327.3 ± 4.827.8 ± 4.226.9 ± 4.00.121
CHA2DS2-VASc score3.4 ± 1.53.5 ± 1.63.3 ± 1.43.4 ± 1.50.405
Time in therapeutic range (%)65.5 ± 17.863.6 ± 16.567.4 ± 18.665.7 ± 18.20.172
Mean week dosage of warfarin (mg)26.0 ± 11.726.7 ± 10.626.0 ± 13.525.7 ± 11.00.812
Mean week dosage of acenocumarol (mg)14.7 ± 6.513.0 ± 5.416.6 ± 6.415.0 ± 7.00.022**
Number of INR analysis, n63.0 (35.0–98.0)74.0 (44.5–104.0)55.5 (32.2–92.5)64.0 (35.0–98.7)0.037***
Mean days between two controls (days)18.9 ± 7.119.1 ± 8.019.0 ± 6.318.6 ± 7.00.716
Past medical history
 Arterial hypertension (%)87.587.389.586.50.680
 Diabetes (%)19.220.618.218.90.850
 History of stroke/TIA (%)14.518.813.312.30.167
 Heart failure (%)14.317.69.115.20.092
 History of MI/CHD (%)20.321.216.821.70.476
 Number of drugs, n5.8 ± 2.45.7 ± 2.45.7 ± 2.55.9 ± 2.30.824
 Anti-platelet therapy (%)10.87.911.812.30.349
 ACE inhibitors/ARBs (%)73.670.774.375.30.582
 β-Blockers (%)42.142.739.743.00.812
 Ca-antagonists (%)33.836.630.933.60.580
 Amiodarone (%)30.730.133.129.80.784

Med-Diet, Mediterranean diet; TIA, transient ischaemic attack; MI, myocardial infarction; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers.

*ANOVA.

**First tertile vs. second and third, P = 0.016.

***First tertile vs. second and third, P = 0.029.

Open in new tab

Table 1

Baseline characteristics of the study cohort

Overall (n = 553)First tertile of Med-Diet 0–4 points (n = 165)Second tertile of Med-Diet 5 points (n = 144)Third tertile of Med-Diet 6–9 points (n = 244)P*
Age (years)72.9 ± 8.372.5 ± 9.072.7 ± 9.373.3 ± 7.00.590
Gender (females) (%)40.042.444.435.70.173
Body mass index (kg/m2)27.3 ± 4.327.3 ± 4.827.8 ± 4.226.9 ± 4.00.121
CHA2DS2-VASc score3.4 ± 1.53.5 ± 1.63.3 ± 1.43.4 ± 1.50.405
Time in therapeutic range (%)65.5 ± 17.863.6 ± 16.567.4 ± 18.665.7 ± 18.20.172
Mean week dosage of warfarin (mg)26.0 ± 11.726.7 ± 10.626.0 ± 13.525.7 ± 11.00.812
Mean week dosage of acenocumarol (mg)14.7 ± 6.513.0 ± 5.416.6 ± 6.415.0 ± 7.00.022**
Number of INR analysis, n63.0 (35.0–98.0)74.0 (44.5–104.0)55.5 (32.2–92.5)64.0 (35.0–98.7)0.037***
Mean days between two controls (days)18.9 ± 7.119.1 ± 8.019.0 ± 6.318.6 ± 7.00.716
Past medical history
 Arterial hypertension (%)87.587.389.586.50.680
 Diabetes (%)19.220.618.218.90.850
 History of stroke/TIA (%)14.518.813.312.30.167
 Heart failure (%)14.317.69.115.20.092
 History of MI/CHD (%)20.321.216.821.70.476
 Number of drugs, n5.8 ± 2.45.7 ± 2.45.7 ± 2.55.9 ± 2.30.824
 Anti-platelet therapy (%)10.87.911.812.30.349
 ACE inhibitors/ARBs (%)73.670.774.375.30.582
 β-Blockers (%)42.142.739.743.00.812
 Ca-antagonists (%)33.836.630.933.60.580
 Amiodarone (%)30.730.133.129.80.784
Overall (n = 553)First tertile of Med-Diet 0–4 points (n = 165)Second tertile of Med-Diet 5 points (n = 144)Third tertile of Med-Diet 6–9 points (n = 244)P*
Age (years)72.9 ± 8.372.5 ± 9.072.7 ± 9.373.3 ± 7.00.590
Gender (females) (%)40.042.444.435.70.173
Body mass index (kg/m2)27.3 ± 4.327.3 ± 4.827.8 ± 4.226.9 ± 4.00.121
CHA2DS2-VASc score3.4 ± 1.53.5 ± 1.63.3 ± 1.43.4 ± 1.50.405
Time in therapeutic range (%)65.5 ± 17.863.6 ± 16.567.4 ± 18.665.7 ± 18.20.172
Mean week dosage of warfarin (mg)26.0 ± 11.726.7 ± 10.626.0 ± 13.525.7 ± 11.00.812
Mean week dosage of acenocumarol (mg)14.7 ± 6.513.0 ± 5.416.6 ± 6.415.0 ± 7.00.022**
Number of INR analysis, n63.0 (35.0–98.0)74.0 (44.5–104.0)55.5 (32.2–92.5)64.0 (35.0–98.7)0.037***
Mean days between two controls (days)18.9 ± 7.119.1 ± 8.019.0 ± 6.318.6 ± 7.00.716
Past medical history
 Arterial hypertension (%)87.587.389.586.50.680
 Diabetes (%)19.220.618.218.90.850
 History of stroke/TIA (%)14.518.813.312.30.167
 Heart failure (%)14.317.69.115.20.092
 History of MI/CHD (%)20.321.216.821.70.476
 Number of drugs, n5.8 ± 2.45.7 ± 2.45.7 ± 2.55.9 ± 2.30.824
 Anti-platelet therapy (%)10.87.911.812.30.349
 ACE inhibitors/ARBs (%)73.670.774.375.30.582
 β-Blockers (%)42.142.739.743.00.812
 Ca-antagonists (%)33.836.630.933.60.580
 Amiodarone (%)30.730.133.129.80.784

Med-Diet, Mediterranean diet; TIA, transient ischaemic attack; MI, myocardial infarction; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers.

*ANOVA.

**First tertile vs. second and third, P = 0.016.

***First tertile vs. second and third, P = 0.029.

Open in new tab

Anticoagulation quality

The median number of INR tests for each patient was 63.0 (interquartile range 35.0–98.0); mean days between two controls were 18.9 ± 7.1 days. Thus, 38 730 blood samples were analysed to obtain INR values.

In the whole cohort, the mean TTR was 65.5 ± 17.8% (Table 1). Among AF patients, 357 (64.6%) were receiving warfarin, and 196 (35.4%) were acenocumarol.

Mediterranean diet adherence and time in therapeutic range

In the entire population, the mean total Med-Diet score was 5.19 ± 1.6. Based on single element consumptions, AF patients had a frequent use of olive oil (90.1%), fruits (88.4%), and vegetables (69.3%), while intake of meat was low (71.2% had <1 serving/day) (Table 2). None of the individual diet components was related to mean TTR.

Table 2

Food frequencies and mean TTRs according to the consumption different food components of the Med-Diet

Consumptions (%)Mean TTR (%)P
YesNo
1. Olive oil (≥1 spoon/day)90.165.6 ± 18.064.4 ± 15.90.618
2. Fruit (≥1 serving/day)88.466.0 ± 18.062.2 ± 16.50.115
3. Vegetables or salad (≥1 serving/day)69.365.5 ± 18.465.6 ± 16.50.942
4. Fruits (≥1 serving/day) and vegetables (≥1 serving/day)67.165.6 ± 18.565.3 ± 16.40.875
5. Legumes (≥2 servings/week)40.766.2 ± 17.665.0 ± 18.00.451
6. Fish (≥3 servings/week)17.966.1 ± 18.565.4 ± 17.70.708
7. Wine (≥1 glass/day)36.065.6 ± 17.265.5 ± 18.20.913
8. Meat (<1 serving/day)71.266.3 ± 17.963.7 ± 17.60.124
9. [White bread (<1/day) and rice (<1/week)] or whole-grain bread (>5/week)38.066.8 ± 17.664.7 ± 18.00.181
Consumptions (%)Mean TTR (%)P
YesNo
1. Olive oil (≥1 spoon/day)90.165.6 ± 18.064.4 ± 15.90.618
2. Fruit (≥1 serving/day)88.466.0 ± 18.062.2 ± 16.50.115
3. Vegetables or salad (≥1 serving/day)69.365.5 ± 18.465.6 ± 16.50.942
4. Fruits (≥1 serving/day) and vegetables (≥1 serving/day)67.165.6 ± 18.565.3 ± 16.40.875
5. Legumes (≥2 servings/week)40.766.2 ± 17.665.0 ± 18.00.451
6. Fish (≥3 servings/week)17.966.1 ± 18.565.4 ± 17.70.708
7. Wine (≥1 glass/day)36.065.6 ± 17.265.5 ± 18.20.913
8. Meat (<1 serving/day)71.266.3 ± 17.963.7 ± 17.60.124
9. [White bread (<1/day) and rice (<1/week)] or whole-grain bread (>5/week)38.066.8 ± 17.664.7 ± 18.00.181

Open in new tab

Table 2

Food frequencies and mean TTRs according to the consumption different food components of the Med-Diet

Consumptions (%)Mean TTR (%)P
YesNo
1. Olive oil (≥1 spoon/day)90.165.6 ± 18.064.4 ± 15.90.618
2. Fruit (≥1 serving/day)88.466.0 ± 18.062.2 ± 16.50.115
3. Vegetables or salad (≥1 serving/day)69.365.5 ± 18.465.6 ± 16.50.942
4. Fruits (≥1 serving/day) and vegetables (≥1 serving/day)67.165.6 ± 18.565.3 ± 16.40.875
5. Legumes (≥2 servings/week)40.766.2 ± 17.665.0 ± 18.00.451
6. Fish (≥3 servings/week)17.966.1 ± 18.565.4 ± 17.70.708
7. Wine (≥1 glass/day)36.065.6 ± 17.265.5 ± 18.20.913
8. Meat (<1 serving/day)71.266.3 ± 17.963.7 ± 17.60.124
9. [White bread (<1/day) and rice (<1/week)] or whole-grain bread (>5/week)38.066.8 ± 17.664.7 ± 18.00.181
Consumptions (%)Mean TTR (%)P
YesNo
1. Olive oil (≥1 spoon/day)90.165.6 ± 18.064.4 ± 15.90.618
2. Fruit (≥1 serving/day)88.466.0 ± 18.062.2 ± 16.50.115
3. Vegetables or salad (≥1 serving/day)69.365.5 ± 18.465.6 ± 16.50.942
4. Fruits (≥1 serving/day) and vegetables (≥1 serving/day)67.165.6 ± 18.565.3 ± 16.40.875
5. Legumes (≥2 servings/week)40.766.2 ± 17.665.0 ± 18.00.451
6. Fish (≥3 servings/week)17.966.1 ± 18.565.4 ± 17.70.708
7. Wine (≥1 glass/day)36.065.6 ± 17.265.5 ± 18.20.913
8. Meat (<1 serving/day)71.266.3 ± 17.963.7 ± 17.60.124
9. [White bread (<1/day) and rice (<1/week)] or whole-grain bread (>5/week)38.066.8 ± 17.664.7 ± 18.00.181

Open in new tab

During the follow-up, the Med-Diet questionnaire was administered a second time to check changes in the adherence to Med-Diet. The questionnaire was administered at a median time of 44.0 (29.0–60.0) months from baseline. In four patients, cardiovascular death occurred before the second administration of the questionnaire. Adherence to the Med-Diet decreased during the follow-up (from 5.19 ± 1.6 to 4.93 ± 1.5, P < 0.001), but the Med-Diet score remained not correlated with TTR (R: 0.028, P = 0.508).

To further investigate the relationship between adherence to Med-Diet and TTR, we divided our AF population according to tertiles of the Med-Diet score (Table 1).

There were no significant differences among Med-Diet tertiles regarding TTR and most clinical characteristics of AF patients with the exception of obesity (Table 1). There was significant lower number of INR analyses observed in patients in the second and third tertile of Med-Diet, compared with the first tertile (Table 1). While there was no difference of warfarin dosage among tertiles of Med-Diet adherence, we found a significant increase of acenocumarol dosage between the first and the other tertiles but the increase was not linear (Table 1).

Correlations and multivariate analysis

Univariate analysis of the factors potentially associated with TTR (Table 3), revealed that diabetes influenced negatively TTR, while the use of angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) was associated with a better TTR.

Table 3

Mean TTR according to the presence of selected variables

Mean TTRP
PresenceAbsence
Gender (female)65.8 ± 18.265.3 ± 17.60.739
Arterial hypertension66.1 ± 17.962.0 ± 16.60.076
Diabetes62.1 ± 16.766.4 ± 17.90.026
History of stroke/TIA64.3 ± 18.565.8 ± 17.70.481
HF62.8 ± 18.766.0 ± 17.60.138
History of MI/CHD62.8 ± 16.966.3 ± 17.90.059
Anti-platelet therapy65.2 ± 17.965.8 ± 17.70.807
ACE inhibitors/ARBs67.2 ± 17.561.5 ± 17.40.001
β-Blockers64.3 ± 17.866.8 ± 17.60.107
Ca-antagonists66.7 ± 17.865.2 ± 17.60.371
Amiodarone65.5 ± 18.366.2 ± 16.20.676
Mean TTRP
PresenceAbsence
Gender (female)65.8 ± 18.265.3 ± 17.60.739
Arterial hypertension66.1 ± 17.962.0 ± 16.60.076
Diabetes62.1 ± 16.766.4 ± 17.90.026
History of stroke/TIA64.3 ± 18.565.8 ± 17.70.481
HF62.8 ± 18.766.0 ± 17.60.138
History of MI/CHD62.8 ± 16.966.3 ± 17.90.059
Anti-platelet therapy65.2 ± 17.965.8 ± 17.70.807
ACE inhibitors/ARBs67.2 ± 17.561.5 ± 17.40.001
β-Blockers64.3 ± 17.866.8 ± 17.60.107
Ca-antagonists66.7 ± 17.865.2 ± 17.60.371
Amiodarone65.5 ± 18.366.2 ± 16.20.676

HF, heart failure; TIA, transient ischaemic attack; MI, myocardial infarction; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers.

Open in new tab

Table 3

Mean TTR according to the presence of selected variables

Mean TTRP
PresenceAbsence
Gender (female)65.8 ± 18.265.3 ± 17.60.739
Arterial hypertension66.1 ± 17.962.0 ± 16.60.076
Diabetes62.1 ± 16.766.4 ± 17.90.026
History of stroke/TIA64.3 ± 18.565.8 ± 17.70.481
HF62.8 ± 18.766.0 ± 17.60.138
History of MI/CHD62.8 ± 16.966.3 ± 17.90.059
Anti-platelet therapy65.2 ± 17.965.8 ± 17.70.807
ACE inhibitors/ARBs67.2 ± 17.561.5 ± 17.40.001
β-Blockers64.3 ± 17.866.8 ± 17.60.107
Ca-antagonists66.7 ± 17.865.2 ± 17.60.371
Amiodarone65.5 ± 18.366.2 ± 16.20.676
Mean TTRP
PresenceAbsence
Gender (female)65.8 ± 18.265.3 ± 17.60.739
Arterial hypertension66.1 ± 17.962.0 ± 16.60.076
Diabetes62.1 ± 16.766.4 ± 17.90.026
History of stroke/TIA64.3 ± 18.565.8 ± 17.70.481
HF62.8 ± 18.766.0 ± 17.60.138
History of MI/CHD62.8 ± 16.966.3 ± 17.90.059
Anti-platelet therapy65.2 ± 17.965.8 ± 17.70.807
ACE inhibitors/ARBs67.2 ± 17.561.5 ± 17.40.001
β-Blockers64.3 ± 17.866.8 ± 17.60.107
Ca-antagonists66.7 ± 17.865.2 ± 17.60.371
Amiodarone65.5 ± 18.366.2 ± 16.20.676

HF, heart failure; TIA, transient ischaemic attack; MI, myocardial infarction; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers.

Open in new tab

In a stepwise multivariable linear regression analysis, diabetes (β: –0.105, P = 0.015) and the use of ACE inhibitor/ARBs (β: 0.153, P < 0.001) were independently associated with TTR, after adjustment for gender (female), arterial hypertension, body mass index, history of stroke/TIA, HF, history of MI/coronary heart disease (CHD), anti-platelet therapy, β-blockers, Ca-antagonists, amiodarone, and total Med-Diet score. Same results were obtained in a model including single foods instead of Med-Diet score (data not shown).

Ischaemic events

An ischaemic cerebro/cardiovascular event (CVE) occurred in 36 patients during the follow-up (2.36%/year): 7 fatal/non-fatal ischaemic stroke, 13 cardiac revascularization, 8 cardiovascular deaths, and 8 fatal/non-fatal MI. Patients experiencing a CVE had significantly lower TTR compared with those without (59.6 ± 15.9 vs. 65.9 ± 17.9, P = 0.029). In addition, Med-Diet score was significantly lower in patients with CVE compared with patients free from events (4.4 ± 1.9 vs. 5.2 ± 1.5, P = 0.004). In particular, a reduction of the risk of CVE was observed for each point of the Med-Diet score [hazard ratio: 0.790 (95% confidence interval, 0.651–0.958), P = 0.017].

Bleeding events

During the follow-up, 116 bleedings were registered (7.7%/year): 30 major (7 cerebral/subdural, 7 gastrointestinal, 4 articular, 5 ocular, 3 haematuria, and 4 muscular) and 86 minor haemorrhages.

Similar TTRs were detected in patients without bleeding (65.0 ± 18.2%) vs. those with minor (66.7 ± 16.8%) or major (69.4 ± 14.0%) bleeding (P = 0.356 among groups). There was no difference regarding Med-Diet adherence score between patients with and without any bleeding event (5.4 ± 1.7 vs. 5.1 ± 1.6, P = 0.137), or those with or without a major bleeding (5.5 ± 1.8 vs. 5.2 ± 1.6, P = 0.277).

Discussion

In this prospective study, we show for the first time that in AF patients Med-Diet has a neutral effect on anticoagulation stability.

Food interactions with the VKAs are a matter of concern as fluctuation in dietary intake of vitamin K may influence the anticoagulant response to these drugs.7 Nevertheless, this interaction has been substantially demonstrated only in patients using specific supplements or herbal infusions.14 In addition, small studies have evaluated the role of specific vitamin K-rich aliments,8,9 but papers reporting the impact of a complete nutritional profile on the quality of anticoagulation control are limited and show equivocal results. One case–control study on 302 outpatients and 300 matched controls found that vitamin K, fat, carbohydrates, and fibre intake did not significantly affect anticoagulation response.4 In a Brazilian group of patients with vascular disease, however, an association between dietary habits, in particular the use of kidney beans, and anticoagulation instability was reported.5

To the best of our knowledge, this is the largest study that examined the effect of a population-based diet on the quality of anticoagulation control in AF patients on chronic VKA treatment. We investigated the relationship between adherence to Med-Diet and TTR overall because this diet is based on ingestion of aliments, such as fruits and green vegetables, which may be rich in vitamin K15 and could theoretically interfere with TTR.

The novel finding of the present study is the lack of Med-Diet food interactions with anticoagulation stability, as no significant differences in TTR were detected among tertiles of Med-Diet. Of note, AF patients who poorly adhered to Med-Diet were more frequently checked for INR values during the follow-up. Even if this should not affect the TTR computation,12 the frequent INR monitoring may be independent from inadequate anticoagulation and simply reflect an individual need for frequent monitoring. Also, patients adhering less to Med-Diet apparently need less acenocumarol compared with the those who adhere more; however, we cannot exclude that this is a play of chance as no difference of warfarin dosage was detected among the tertiles of Med-Diet adherence. This finding needs to be further investigated and interpreted with an interventional trial.

In our study, there was a good average TTR in patients in the highest tertile of Med-Diet, which is characterized by high intake of fruits and vegetables, suggesting that the aliments assumed with the Med-Diet contain a vitamin K amount that does not affect the anticoagulant response to VKA.

A possible interpretation of this apparent paradox is that Med-Diet is rich of vitamin E, particularly in some of its components such as extra virgin olive oil.16 Thus, vitamin E seems to exert an anticoagulant effect by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors.17 In this context, it is worth noting that in AF anticoagulated patients, we previously demonstrated that serum levels of vitamin E linearly increase with Med-Diet adherence,13 and are associated inversely with ischaemic events,18 and directly with bleeding events.13 It may be possible, therefore, that in the Med-Diet the pro-coagulant effect of aliments rich in vitamin K, which gamma-carboxylates vitamin K-dependent factors, may be counterbalanced by its high vitamin E content.

Previous data from the ROCKET trial showed that diabetes, CHD, or HF were negatively associated with TTR.19 While we confirm the negative association between diabetes and TTR, only a trend for a lower TTR in patients with a clinical history of CHD or HF was detected.

An unexpected finding was the positive association between ACE inhibitors/ARBs and TTR. We interpreted this positive association as a mere reflection of a better control of blood pressure, as suggested in the ROCKET trial by the inverse association between systolic blood pressure and TTR.19

The study has clinical implications, as it shows that Med-Diet does not interfere with anticoagulation and could represent a dietary option for AF on VKAs. The suggestion to follow the Med-Diet may also be of useful given some evidence to indicate that such a diet is associated with a lower risk of developing diabetes and metabolic syndrome, and with a reduction in stroke and MI risk20 (Figure 1). In accordance with this, adherence to Med-Diet was associated with lower risk of CVEs and neutral effect on bleeding.

Figure 1

Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists (3)

Open in new tabDownload slide

Potential benefit of Mediterranean diet in the management of atrial fibrillation patients.

Limitations

Adherence to Med-Diet was assessed by a short semi-quantitative questionnaire that not fully estimates the exact amount of each single food and, in particular, the consumption of leafy green vegetables, which have the highest content of vitamin K. An interventional study with a Med-Diet would be useful to further support the results of the present study.

Our suggestion to follow a Med-Diet is limited to AF patients on VKAs and the results stem from a single-centre study, therefore, a multicentre study needs to be done to support our conclusion.

Finally, the effect of Med-Diet should be explored also in AF treated with non-vitamin K oral anticoagulants to see if it is associated with a similar beneficial effect on cardiovascular risk.

Conclusion

In conclusion, adherence Med-Diet is not associated with changes in TTR in a cohort of AF patients suggesting that food contained in such diet does not interfere with VKAs.

Funding

This study was supported by Sapienza University of Rome, Grant Code ‘Pignatelli Progetto Ricerca Sapienza 2011’.

Conflict of interest: none declared.

References

1

White

HD

Gruber

M

Feyzi

J

Kaatz

S

Tse

HF

Husted

S

et al.

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V

.

Arch Intern Med

2007

;

167

:

239

45

.

2

Pugh

D

Pugh

J

Mead

GE

.

Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review

.

Age Ageing

2011

;

40

:

675

83

.

3

Chang

CH

Wang

YW

Yeh Liu

PY

Kao Yang

YH

.

A practical approach to minimize the interaction of dietary vitamin K with warfarin

.

J Clin Pharm Ther

2014

;

39

:

56

60

.

4

Penning-van Beest

FJ

Geleijnse

JM

van Meegen

E

Vermeer

C

Rosendaal

FR

Stricker

BH

.

Lifestyle and diet as risk factors for overanticoagulation

.

J Clin Epidemiol

2002

;

55

:

411

7

.

5

Custodio das Dores

SM

Booth

SL

Martini

LA

de Carvalho Gouvea

VH

Padovani

CR

de Abreu Maffei

FH

et al.

Relationship between diet and anticoagulant response to warfarin: a factor analysis

.

Eur J Nutr

2007

;

46

:

147

54

.

6

Kalra

PA

Cooklin

M

Wood

G

O'Shea

GM

Holmes

AM

.

Dietary modification as cause of anticoagulation instability

.

Lancet

1988

;

2

:

803

.

7

Ageno

W

Gallus

AS

Wittkowsky

A

Crowther

M

Hylek

EM

Palareti

G

et al.

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

.

Chest

2012

;

141

:

e44S

88S

.

8

Wells

PS

Holbrook

AM

Crowther

NR

Hirsh

J

.

Interactions of warfarin with drugs and food

.

Ann Intern Med

1994

;

121

:

676

83

.

9

Franco

V

Polanczyk

CA

Clausell

N

Rohde

LE

.

Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols

.

Am J Med

2004

;

116

:

651

6

.

10

Pignatelli

P

Pastori

D

Farcomeni

A

Nocella

C

Bartimoccia

S

Vicario

T

et al.

Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients

.

Clin Nutr

2014

;

.

Google Scholar

OpenURL Placeholder Text

Crossref

11

Martinez-Gonzalez

MA

Fernandez-Jarne

E

Serrano-Martinez

M

Wright

M

Gomez-Gracia

E

.

Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet

.

Eur J Clin Nutr

2004

;

58

:

1550

2

.

12

Rosendaal

FR

Cannegieter

SC

van der Meer

FJ

Briet

E

.

A method to determine the optimal intensity of oral anticoagulant therapy

.

Thromb Haemost

1993

;

69

:

236

9

.

Google Scholar

OpenURL Placeholder Text

13

Pastori

D

Carnevale

R

Cangemi

R

Saliola

M

Nocella

C

Bartimoccia

S

et al.

Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study

.

J Am Heart Assoc

2013

;

2

:

e000364

.

14

Wittkowsky

AK

.

Dietary supplements, herbs and oral anticoagulants: the nature of the evidence

.

J Thromb Thrombolysis

2008

;

25

:

72

7

.

15

Booth

SL

Pennington

JA

Sadowski

JA

.

Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA Total Diet Study

.

J Am Diet Assoc

1996

;

96

:

149

54

.

16

Rock

CL

Jacob

RA

Bowen

PE

.

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids

.

J Am Diet Assoc

1996

;

96

:

693

702

;

quiz 703–694

.

17

Corrigan

JJ

Jr

Ulfers

LL

.

Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency

.

Am J Clin Nutr

1981

;

34

:

1701

5

.

Google Scholar

OpenURL Placeholder Text

18

Cangemi

R

Pignatelli

P

Carnevale

R

Corazza

GR

Pastori

D

Farcomeni

A

et al.

Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation

.

Int J Cardiol

2013

;

168

:

3241

7

.

19

Singer

DE

Hellkamp

AS

Piccini

JP

Mahaffey

KW

Lokhnygina

Y

Pan

G

et al.

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial

.

J Am Heart Assoc

2013

;

2

:

e000067

.

Google Scholar

OpenURL Placeholder Text

20

Estruch

R

Ros

E

Salas-Salvado

J

Covas

MI

Corella

D

Aros

F

et al.

Primary prevention of cardiovascular disease with a Mediterranean diet

.

N Engl J Med

2013

;

368

:

1279

90

.

Author notes

These authors contributed equally.

These are joint senior authors.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Topic:

  • angiotensin-converting enzyme inhibitors
  • anticoagulation
  • atrial fibrillation
  • myocardial infarction
  • olive oil
  • mediterranean diet
  • diabetes mellitus
  • ischemic stroke
  • angiotensin receptor antagonists
  • diabetes mellitus, type 2
  • diet
  • follow-up
  • fruit
  • international normalized ratio
  • meat
  • vegetables
  • therapeutic index
  • cardiovascular event
  • vitamin k antagonists
  • cardiovascular death
  • linear regression

Issue Section:

Atrial fibrillation

Download all slides

Advertisem*nt intended for healthcare professionals

Citations

Views

2,497

Altmetric

More metrics information

Metrics

Total Views 2,497

1,918 Pageviews

579 PDF Downloads

Since 2/1/2017

Month: Total Views:
February 2017 2
March 2017 11
April 2017 8
June 2017 4
July 2017 3
August 2017 5
September 2017 11
October 2017 1
November 2017 13
December 2017 22
January 2018 34
February 2018 24
March 2018 29
April 2018 43
May 2018 32
June 2018 36
July 2018 44
August 2018 37
September 2018 18
October 2018 34
November 2018 25
December 2018 22
January 2019 28
February 2019 31
March 2019 51
April 2019 44
May 2019 43
June 2019 25
July 2019 26
August 2019 31
September 2019 36
October 2019 21
November 2019 27
December 2019 26
January 2020 39
February 2020 39
March 2020 28
April 2020 44
May 2020 14
June 2020 27
July 2020 27
August 2020 19
September 2020 28
October 2020 21
November 2020 25
December 2020 27
January 2021 26
February 2021 36
March 2021 33
April 2021 30
May 2021 43
June 2021 28
July 2021 34
August 2021 27
September 2021 34
October 2021 28
November 2021 22
December 2021 32
January 2022 32
February 2022 46
March 2022 27
April 2022 48
May 2022 32
June 2022 55
July 2022 25
August 2022 39
September 2022 32
October 2022 48
November 2022 32
December 2022 44
January 2023 34
February 2023 36
March 2023 40
April 2023 38
May 2023 26
June 2023 26
July 2023 25
August 2023 40
September 2023 31
October 2023 23
November 2023 28
December 2023 35
January 2024 38
February 2024 45
March 2024 14

Citations

Powered by Dimensions

10 Web of Science

Altmetrics

×

Email alerts

Article activity alert

Advance article alerts

New issue alert

In progress issue alert

Receive exclusive offers and updates from Oxford Academic

More on this topic

Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits

The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation

Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry

Citing articles via

Google Scholar

  • Latest

  • Most Read

  • Most Cited

Prognostic Implications of Premature Ventricular Contractions and Non-sustained Ventricular Tachycardia in Light-Chain Cardiac Amyloidosis
Aveir VR real-world performance and chronic pacing threshold prediction using mapping and fixation electrical data
Central obesity as a potential causal risk factor for atrial fibrillation: Evidence from Mendelian randomization study
Strategies to improve AV synchrony in patients with a Micra AV leadless pacemaker
Premature ventricular contractions in children and young adults: natural history and clinical implications

More from Oxford Academic

Cardiovascular Medicine

Clinical Medicine

Medicine and Health

Books

Journals

Advertisem*nt intended for healthcare professionals

Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists (2024)

References

Top Articles
Latest Posts
Article information

Author: Dean Jakubowski Ret

Last Updated:

Views: 6190

Rating: 5 / 5 (50 voted)

Reviews: 89% of readers found this page helpful

Author information

Name: Dean Jakubowski Ret

Birthday: 1996-05-10

Address: Apt. 425 4346 Santiago Islands, Shariside, AK 38830-1874

Phone: +96313309894162

Job: Legacy Sales Designer

Hobby: Baseball, Wood carving, Candle making, Jigsaw puzzles, Lacemaking, Parkour, Drawing

Introduction: My name is Dean Jakubowski Ret, I am a enthusiastic, friendly, homely, handsome, zealous, brainy, elegant person who loves writing and wants to share my knowledge and understanding with you.